E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin (original) (raw)

• Macdonald JS, Astrow AB . Adjuvant therapy of colon cancer. Semin Oncol. 2001;28:30–40.
  Article CAS Google Scholar
• Grivicich I, Mans DR, Peters GJ, et al. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res. 2001;34:1087–1103.
  Article CAS Google Scholar
• Saltz L . Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. Oncology. 2000;14:47–50.
  CAS PubMed Google Scholar
• Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002;62:924–931.
  CAS PubMed Google Scholar
• Schmitt CA, Lowe SW . Apoptosis and chemoresistance in transgenic cancer models. J Mol Med. 2002;80:137–146.
  Article CAS Google Scholar
• Poulain L, Lincet H, Duigou F, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer. 1998;78:454–463.
  Article CAS Google Scholar
• Lutzker SG, Levine AJ . Apoptosis and cancer chemotherapy. Cancer Treat Res. 1996;87:345–356.
  Article CAS Google Scholar
• Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271–291.
  Article CAS Google Scholar
• Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993;11:909–913.
  Article CAS Google Scholar
• Gupta M, Abdel-Megeed M, Hoki Y, et al. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol. 1995;48:658–665.
  CAS PubMed Google Scholar
• Liu LF, Desai SD, Li TK, et al Mechanism of action of camptothecin. Ann NY Acad Sci. 2000;922:1–10.
  Article CAS Google Scholar
• Avemann K, Knippers R, Koller T, et al. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol. 1988;8:3026–3034.
  Article CAS Google Scholar
• Horwitz SB, Horwitz MS . Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973;33:2834–2836.
  CAS PubMed Google Scholar
• Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994;12:530–542.
  Article CAS Google Scholar
• Hsiang YH, Lihou MG, Liu LF . Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49(18):5077–5082.
  CAS PubMed Google Scholar
• Goldwasser F, Bae I, Valenti M, et al. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Can Res. 1995;55:2116–2121.
  CAS Google Scholar
• Sugimoto Y, Tsukahara S, Oh-hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990;50:6925–6930.
  CAS PubMed Google Scholar
• Benedetti P, Fiorani P, Capuani L, et al. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 1993; 53:4343–4348.
  CAS PubMed Google Scholar
• Rubin E, Pantazis P, Bharti A, et al. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem. 1994; 269:2433–2439.
  CAS PubMed Google Scholar
• Girling R, Bandara LR, Ormondroyd E, et al. A new component of transcription factor DRTF1/E2F. Nature. 1993; 362:83–87.
  Article CAS Google Scholar
• De Gregori J, Kowalik T, Nevins JR . Cellular targets for activation by the E2F-1 transcription factor include DNA synthesis and G1/S-regulatory genes. Mol Cell Biol. 1995;5: 4215–4224.
  Article Google Scholar
• Hunt KK, Deng J, Liu TJ, et al. Adenovirus-mediated overexpresion of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997;57:4722–4726.
  CAS PubMed Google Scholar
• Fueyo J, Gomez-Manzano C, Yung WK, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med. 1998;4:685–690.
  Article CAS Google Scholar
• Dong YB, Yang HL, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 1999;86:2021–2033.
  Article CAS Google Scholar
• Yang HL, Dong YB, Elliott MJ, et al. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res. 2000;6:1579–1589.
  CAS PubMed Google Scholar
• Yang HL, Dong YB, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in mdm2-overexpressing tumor cells. Clin Cancer Res. 1999;5:2242–2250.
  CAS PubMed Google Scholar
• Dong YB, Yang HL, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 2002;62:1776–1783.
  CAS PubMed Google Scholar
• Yang HL, Dong YB, Elliott MJ, et al. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells. Cancer Gene Ther. 2001;8:241–251.
  Article CAS Google Scholar
• Meng RD, Phillips P, EL-Deiry WS . P53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamyicn. Int J Oncol. 1999;14:5–14.
  CAS PubMed Google Scholar
• Banerjee D, Schnieders B, Fu JZ, et al. Role of E2F-1 in chemosensitivity. Cancer Res. 1998;58:4292–4296.
  CAS PubMed Google Scholar
• Nip J, Strom DK, Lee BE, et al. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol. 1997; 17:1049–1056.
  Article CAS Google Scholar
• O'Connor DJ, Lu X . Stress signals induce transcriptionally inactive E2F-1 independently of p53 and RB. Oncogene. 2000;19:2369–2376.
  Article CAS Google Scholar
• Elliott MJ, Dong YB, Yang HL, et al. E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin Cancer Res. 2001;7:3590–3597.
  CAS PubMed Google Scholar
• Goldwasser F, Shimizu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996;56:4430–4437.
  CAS PubMed Google Scholar
• Jaks V, Joers A, Kristjuhan A, Maimets T . p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin. Oncogene. 2001;20:1212–1219.
  Article CAS Google Scholar
• Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001;7:4209–4219.
  CAS PubMed Google Scholar
• Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Na Med. 1997;3:1034–1036.
  Article CAS Google Scholar
• Lamb JR, Friend SH . Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nat Med. 1997;3:962–963.
  Article CAS Google Scholar
• Wu X, Levine AJ . p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA. 1994;91:3602–3606.
  Article CAS Google Scholar
• Kowalik TF, DeGregori J, Schwarz JK, et al. E2F-1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol. 1995;69:2491–2500.
  CAS PubMed PubMed Central Google Scholar
• Hiebert SW, Packham G, Strom DK, et al. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol. 1995;15:6864–6874.
  Article CAS Google Scholar
• Holmberg S, Helin K, Sehested M, et al. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene. 1998;17:143–156.
  Article CAS Google Scholar
• Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992;89:7491–7495.
  Article CAS Google Scholar
• Shao RG, Cao CX, Nieves-Neira W, et al. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene. 2001;20:1852–1859.
  Article CAS Google Scholar
• Giovanella BC, Hinz HR, Kozielski AJ, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 1991;51:3052–3055.
  CAS PubMed Google Scholar
• Jordan-Sciutto KL, Hall DJ . A mutant E2F-1 transcription factor that affects the phenotype of NIH3T3 fibroblasts inefficiency associates with cyclin A-cdk2. Biochem Cell Bio. 1998;76:37–44.
  Article CAS Google Scholar
• Chen AY, Liu LF . DNA tpoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218.
  Article CAS Google Scholar